Introduction: ADCC by natural killer (NK) cells is a key mechanism for several clinically successful tumor-targeting therapeutic antibodies. Most patients, however, have limited responses to this therapy and/or develop resistance. NK cells exclusively recognize IgG by their low-affinity FcγR CD16A. Areas covered: We describe in this editorial a novel recombinant FcγR that consists of CD64, the only high affinity IgG receptor, and the transmembrane and cytoplasmic regions of CD16A, a potent activating receptor. CD64/16A was expressed in engineered iPSCs that were differentiated into NK cells (referred to as iNK cells). Expert opinion: iNK-CD64/16A cells in combination with therapeutic antibodies provide a universal tumor antigen targeting approach and potential off-the-shelf cell therapy to treat various malignancies.
Bibliographical noteFunding Information:
This paper was funded by the National Institutes of Health, including R01CA203348 and R21AI125729, and the Minnesota Ovarian Cancer Alliance.
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
- Fc receptor
- Natural killer cells
- cell therapy
- mAb therapy
- stem cell